Tumor Microenvironment: No Effector T Cells without Dendritic Cells
| Autor: | Christina Pfirschke, Hsin-Wei Liao, Marie Siwicki, Mikael J. Pittet |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Cancer Research Chemokine T-Lymphocytes medicine.medical_treatment Article 03 medical and health sciences 0302 clinical medicine Tumor Microenvironment medicine Tumor Microenvironment/immunology Humans Tumor microenvironment Antitumor immunity biology Chemokines/immunology Effector Dendritic Cells Cell Biology Immunotherapy T-Lymphocytes/immunology Cell biology 030104 developmental biology Oncology Dendritic Cells/immunology 030220 oncology & carcinogenesis Cancer cell biology.protein Chemokines |
| Zdroj: | Cancer Cell, Vol. 31, No 5 (2017) pp. 614-615 |
| ISSN: | 1535-6108 |
| DOI: | 10.1016/j.ccell.2017.04.007 |
| Popis: | Effector T cells have the capability of recognizing and killing cancer cells. However, whether tumors can become immune-resistant through exclusion of effector T cells from the tumor microenvironment is not known. By using a tumor model resembling non-T cell-inflamed human tumors, we assessed whether adoptive T cell transfer might overcome failed spontaneous priming. Flow cytometric assays combined with intra-vital imaging indicated failed trafficking of effector T cells into tumors. Mechanistically, this was due to absence of CXCL9/10, which we found to be produced by CD103+ dendritic cells (DC) in T cell-inflamed tumors. Our data indicate that lack of CD103+ DC within the tumor microenvironment dominantly resists the effector phase of an anti-tumor T cell response, contributing to immune escape. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|